To the full analysis
Buyback calculator for Xenon Pharmaceuticals
Xenon Pharmaceuticals stock: key metrics
XENEXenon Pharmaceuticals had an operating margin of −4,974.3% and a return on invested capital (ROIC) of −34.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2011 | 100.0% | −175.1% | −173.3% |
| 2012 | 48.8% | −22.0% | −30.1% |
| 2013 | 77.3% | 35.5% | 44.0% |
| 2014 | 79.2% | 39.1% | 45.9% |
| 2015 | 82.3% | −60.1% | −101.1% |
| 2016 | 38.2% | −1,376.4% | −1,275.5% |
| 2017 | −8,122.8% | −10,474.3% | −9,872.7% |
| 2018 | no data | no data | no data |
| 2019 | 100.0% | −627.0% | −609.1% |
| 2020 | 100.0% | −97.3% | −89.7% |
| 2021 | 100.0% | −428.4% | −427.8% |
| 2022 | 100.0% | −1,368.9% | −1,328.9% |
| 2023 | no data | no data | no data |
| 2024 | no data | no data | no data |
| 2025 | 66.1% | −4,974.3% | −4,612.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2011 | 0.0% | no data | 0.0% |
| 2012 | −34.1% | −5.6% | −6.8% |
| 2013 | 49.9% | 24.0% | 22.1% |
| 2014 | 17.9% | 20.3% | 14.9% |
| 2015 | −25.8% | −11.0% | −24.6% |
| 2016 | −36.0% | −31.3% | −34.1% |
| 2017 | −85.4% | −48.2% | −66.6% |
| 2018 | −33.4% | −37.3% | −28.2% |
| 2019 | −45.2% | −29.8% | −28.2% |
| 2020 | −16.8% | −17.5% | −15.2% |
| 2021 | −14.3% | −17.0% | −13.8% |
| 2022 | −17.4% | −15.8% | −16.6% |
| 2023 | −19.7% | −76.8% | −18.9% |
| 2024 | −31.0% | −26.0% | −29.4% |
| 2025 | −59.5% | −34.6% | −35.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.